Rapamycin Augmentation of Chronic Ketamine as a Novel Treatment for Complex Regional Pain Syndrome

[1]  S. Gupta,et al.  Differential Regulation of Two Arms of mTORC1 Pathway Fine-Tunes Global Protein Synthesis in Resting B Lymphocytes , 2022, International journal of molecular sciences.

[2]  A. Kaye,et al.  Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug. , 2022, Health psychology research.

[3]  A. Liston,et al.  Brain-resident regulatory T cells and their role in health and disease. , 2022, Immunology letters.

[4]  Yuko Fujita,et al.  Nuclear factor of activated T cells 4 in the prefrontal cortex is required for prophylactic actions of (R)-ketamine , 2022, Translational Psychiatry.

[5]  A. De Grassi,et al.  N‐acetylaspartate release by glutaminolytic ovarian cancer cells sustains protumoral macrophages , 2021, EMBO reports.

[6]  A. Paladini,et al.  Complex Regional Pain Syndrome: A Comprehensive Review , 2021, Pain and Therapy.

[7]  G. Grigoropoulos,et al.  Use of Ketamine Infusions for Treatment of Complex Regional Pain Syndrome: A Systematic Review , 2021, medRxiv.

[8]  T. Guo,et al.  IL-6 signaling mediates the germinal center response, IgM production and nociceptive sensitization in male mice after tibia fracture , 2021, Brain, Behavior, and Immunity.

[9]  Dongya Zhang,et al.  Regulating T Cell Population Alleviates SLE by Inhibiting mTORC1/C2 in MRL/lpr Mice , 2021, Frontiers in Pharmacology.

[10]  N. Calcutt,et al.  Fecal transplantation and butyrate improve neuropathic pain, modify immune cell profile, and gene expression in the PNS of obese mice , 2020, Proceedings of the National Academy of Sciences.

[11]  J. Aronowski,et al.  Excitatory pathway engaging glutamate, calcineurin, and NFAT upregulates IL-4 in ischemic neurons to polarize microglia , 2020, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  S. Southwick,et al.  Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin , 2020, Neuropsychopharmacology.

[13]  Yuko Fujita,et al.  Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1 , 2020, Translational Psychiatry.

[14]  T. Guo,et al.  Complex regional pain syndrome patient IgM has pronociceptive effects in the skin and spinal cord of tibia fracture mice. , 2019, Pain.

[15]  A. McIntosh,et al.  Genome-wide association study of multisite chronic pain in UK Biobank , 2019, PLoS genetics.

[16]  B. Prabhakar,et al.  Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells. , 2019, Cellular immunology.

[17]  V. Shaygannejad,et al.  Promising effect of rapamycin on multiple sclerosis. , 2018, Multiple sclerosis and related disorders.

[18]  Guihua Liu,et al.  The PI3K/AKT pathway in obesity and type 2 diabetes , 2018, International journal of biological sciences.

[19]  I. Amit,et al.  Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration , 2018, Cell.

[20]  S. Faraone,et al.  Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial , 2018, The Lancet.

[21]  N. Shenker,et al.  A randomised placebo-controlled Phase III multicentre trial: low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome (LIPS trial) , 2017 .

[22]  H. Krämer,et al.  Identification of KRT16 as a target of an autoantibody response in complex regional pain syndrome , 2017, Experimental Neurology.

[23]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[24]  B. Blanco,et al.  Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development , 2016, Journal of Hematology & Oncology.

[25]  J. Clark,et al.  New Concepts in Complex Regional Pain Syndrome. , 2016, Hand clinics.

[26]  Ting-Ting Huang,et al.  Differential Efficacy of Ketamine in the Acute versus Chronic Stages of Complex Regional Pain Syndrome in Mice , 2015, Anesthesiology.

[27]  Ting-Ting Huang,et al.  Sex differences in a Murine Model of Complex Regional Pain Syndrome , 2015, Neurobiology of Learning and Memory.

[28]  U. Bommhardt,et al.  NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells , 2014, Cell Communication and Signaling.

[29]  J. Simpkins,et al.  mTOR Signaling Inhibition Modulates Macrophage/Microglia-Mediated Neuroinflammation and Secondary Injury via Regulatory T Cells after Focal Ischemia , 2014, The Journal of Immunology.

[30]  A. Goebel,et al.  A CRPS-IgG-transfer-trauma model reproducing inflammatory and positive sensory signs associated with complex regional pain syndrome , 2014, PAIN®.

[31]  Dudley Lamming,et al.  The TSC-mTOR pathway regulates macrophage polarization , 2013, Nature Communications.

[32]  T. Spentzas,et al.  Rapamycin Augments the NMDA-Mediated TNF Suppression of MRSA-Stimulated RAW264.7 Murine Macrophages , 2012, International journal of inflammation.

[33]  C. Parent,et al.  Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. , 2011, Blood.

[34]  J. Sheu,et al.  Inhibitory Effects of Ketamine on Lipopolysaccharide-Induced Microglial Activation , 2009, Mediators of inflammation.

[35]  B. Beilin,et al.  Low-dose ketamine affects immune responses in humans during the early postoperative period. , 2007, British journal of anaesthesia.

[36]  R. Harden,et al.  Proposed new diagnostic criteria for complex regional pain syndrome. , 2007, Pain medicine.

[37]  E. Benedetti,et al.  RISK FACTORS FOR WOUND HEALING COMPLICATIONS IN SIROLIMUS-TREATED RENAL TRANSPLANT RECIPIENTS. , 2006, Transplantation proceedings.

[38]  R. Quibell,et al.  Ketamine: a misunderstood analgesic? , 2006, BMJ : British Medical Journal.

[39]  S. di Paolo,et al.  Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. , 2005, Journal of the American Society of Nephrology : JASN.

[40]  V. Ng,et al.  Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma * , 2004, Pediatric transplantation.

[41]  R. Kaplan,et al.  Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. , 1999, Archives of dermatology.

[42]  David R Fernandez,et al.  Metabolic control of T cell activation and death in SLE. , 2009, Autoimmunity reviews.